 Acute graft versus host disease continues to be a major cause of morbidity and mortality after allogeneic hematopoietic cell transplant in pediatric patients and limits broader application of the therapy . Pediatric HCT patients have faced major obstacles to access clinical trials that test new agents for GVHD prevention and treatment . According to a recent search only 6 clinical trials of interventions for prevention or treatment of acute GVHD were conducted specifically in pediatric patients in the United States over the past decade with 8 internationally . In this review we summarize the studies that were performed and specifically enrolled and reported on pediatric patients after allogeneic HCT and provide a listing of studies currently under way .

@highlight Acute graft versus host disease GVHD continues to be a major cause of morbidity and mortality after allogeneic hematopoietic cell transplant HCT in pediatric patients.
@highlight Pediatric HCT patients have faced major obstacles to access clinical trials that test new agents for GVHD prevention and treatment.
@highlight Clinical trials in which adult and pediatric endpoints are the same succeed in meeting their primary endpoint more often than trials that do not combine all ages.
